Tsung-Jung Liang

Dr. Tsung-Jung Liang

Kaohsiung Veterans General Hospital
orcid
MD, FACS

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
Tsung-Jung LiangTsung-Jung Liang
Tsung-Jung Liang
SLShiuh‐Inn Liu
Shiuh‐Inn Liu
KMKing‐Tong Mok
King‐Tong Mok
Hon-Yi ShiHon-Yi Shi
Hon-Yi Shi

1 September 2017 in International Journal of Surgery
Verified
Journal Article
Closed access
JHJui Hu Hsiao
Jui Hu Hsiao
CTCheng-Chung Tsai
Cheng-Chung Tsai
Tsung-Jung LiangTsung-Jung Liang
Tsung-Jung Liang
CCChia-Ling Chiang
Chia-Ling Chiang
HLHuei-Lung Liang
Huei-Lung Liang
BWBeing-Whey Wang
Being-Whey Wang
Recurrence rate after curative surgical resection of Hepatocellular carcinoma (HCC) remains high. Postoperative hepatic arterial infusion chemotherapy (HAIC) has been suggested to improve survival. This study is to investigate the efficacy of HAIC in the patients with poor tumor factors such as vascular invasion or multiplicity. From 2006 to 2014, 221 patients with HCC undergoing hepatectomy and pathologically staged as ≧ T2 (American Joint Committee on Cancer TNM staging system, 7th edition) were included. 61 patients received adjuvant HAIC with 5-fluorouracil, cisplatin, and epirubicin. 160 patients received surgery alone. The overall survival time (OST) and disease free survival time (DFST) were compared between the two groups. In all patients, the multivariate analysis of survival data showed that resection margin less than 10 mm was the independent poor prognostic factors. The median OST and DFST between the HAIC and surgery alone groups were 56.4 vs. 56.9 months (p = 0.76), and 50.6 vs. 54.5 months (p = 0.905), respectively. There was no significant difference. For patients with multiple tumors and concomitantly microvascular invasion, the OST was better in the HAIC group (69.7 vs. 54.6 months, p < 0.05). Based on the image and operative finding, we classified multiple HCC's into two types. Type A: multiple small nodules were close to each other or a huge tumor with several satellite nodules. Type B: two or more tumors scattering in separate segments. Our study showed that type A group benefits from adjuvant HAIC much more than type B. (the median OST in type A versus type B were 85.06 vs. 41.53 months, p = 0.0036). The surgical outcome for the patients with multiple HCC's and vascular invasion was poor. Our study showed adjuvant HAIC was beneficial in these patients and formed the basis for further randomized controlled trials.

2 February 2017 in Gastric Cancer
Verified
Journal Article
Closed access
PDF file
Tsung-Jung LiangTsung-Jung Liang
Tsung-Jung Liang
SLShiuh-Inn Liu
Shiuh-Inn Liu
YCYu-Chia Chen
Yu-Chia Chen
PCPo-Min Chang
Po-Min Chang
WHWei-Chun Huang
Wei-Chun Huang
ICI-Shu Chen Chen
I-Shu Chen Chen

27 February 2021 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
Tsung-Jung LiangTsung-Jung Liang
Tsung-Jung Liang
NWNai‐Yu Wang
Nai‐Yu Wang
CTChung‐Yu Tsai
Chung‐Yu Tsai
SLShiuh‐Inn Liu
Shiuh‐Inn Liu
ICI-Shu Chen Chen
I-Shu Chen Chen

14 August 2013 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
Tsung-Jung LiangTsung-Jung Liang
Tsung-Jung Liang
BWBeing-Whey Wang
Being-Whey Wang
SLShiuh-Inn Liu
Shiuh-Inn Liu
MYMing-Hsin Yeh
Ming-Hsin Yeh
YCYu-Chia Chen
Yu-Chia Chen
HCHong-Tai Chang
Hong-Tai Chang
Background: The aim of this study was to evaluate the recurrence pattern after skin-sparing mastectomy (SSM) and immediate breast reconstruction (IBR) using transverse rectus abdominis musculocutaneous (TRAM) flap in patients with invasive breast cancer. Methods: From 1995 to 2010, patients with invasive breast cancer who underwent SSM followed by IBR using TRAM flap were retrospectively reviewed. The pattern of the first recurrence event was recorded. Results: We identified 249 consecutive patients with invasive breast cancer, two-thirds of whom (67.1%) were diagnosed with stage II or stage III disease. During a median follow-up period of 53 months, three (1.2%) local, 13 (5.2%) regional, 34 (13.7%) distant, and five (2.0%) concurrent locoregional and distant recurrences were observed. The median time to recurrences was 26 months (range, 2 to 70 months) for all recurrences, 23 months (range, 2 to 64 months) for locoregional recurrences, and 26 months (range, 8 to 70 months) for distant recurrences. All local recurrent lesions were detectable by careful physical examination, and detection of local recurrence suggested the presence of distant metastasis (60.0%). In contrast to distant metastasis, the risk of locoregional recurrence did not increase significantly with an increase in disease stage. The 5-year overall, locoregional relapse-free, and distant relapse-free survival rates were 89.7%, 90.8%, and 81.6%, respectively. Conclusions: SSM followed by immediate reconstruction using TRAM flap is an oncologically safe procedure even in patients with advanced-stage disease. Detection of local recurrence is crucial and can be aided by a thorough physical examination.

1 November 2012 in Journal of the Chinese Medical Association
Verified
Journal Article
Closed access
Tsung-Jung LiangTsung-Jung Liang
Tsung-Jung Liang
BWBeing-Whey Wang
Being-Whey Wang
SLShiuh-Inn Liu
Shiuh-Inn Liu
NCNan-Hua Chou
Nan-Hua Chou
CTCheng-Chung Tsai
Cheng-Chung Tsai
KMKing-Tong Mok
King-Tong Mok
The significance of lymph node involvement regarding the prognosis of primary duodenal adenocarcinoma remains controversial. This study aims to evaluate the prognostic accuracy of nodal metastasis using the seventh edition American Joint Committee on Cancer staging system in patients with primary duodenal adenocarcinoma. Between 1993 and 2010, 36 patients who had undergone surgical resection for primary duodenal adenocarcinoma at the Kaohsiung Veterans General Hospital were retrospectively reviewed. The median disease-free survival for all patients was 19 months and the median overall survival was 21 months. Lymph node metastases were found in 26 (72%) of the patients, and 14 patients (39%) patients had in excess of three positive lymph nodes (N2). Patients with N2 disease had significantly reduced overall survival, as compared to patients with three or fewer positive lymph nodes (N1; p = 0.036). In univariate analysis, factors including age >75 years, body weight loss, tumor size ≤ 4 cm, N2 disease and lymph node ratio >0.4 predicted shorter overall survival. Multivariate analysis demonstrated that N2 and lymph node ratio >0.4 are significant risk factors associated with overall survival (p = 0.026 and p = 0.042 respectively). N2 is also the only independent predictive factor for disease-free survival (p = 0.023). Subdivision of metastatic lymph nodes into N1 and N2 improves predictive ability. The seventh edition American Joint Committee on Cancer staging system is applicable in the present study with regard to the prediction of the prognosis for primary duodenal adenocarcinoma.